Pórszász, RóbertJu, Won Hee2023-03-102023-03-102022-05-20https://hdl.handle.net/2437/347812Hyperlipidemia is the best-established risk factor for cardiovascular disease (CVD), the leading cause of death worldwide. Lowering LDL-C levels, primarily with statins has been the cornerstone of lipid-lowering therapy. However, over the past few years, new therapeutic approaches have emerged to reduce the additional residual risk of CVD. This thesis provides a general overview of lipid and lipoprotein metabolisms and their impact on CVD. It also summarized the conventional lipid-lowering drugs and the latest information on the novel treatment approaches for hyperlipidemia that target LDL-C levels and other atherogenic lipid fractions.41enDyslipidemiaCardiovascular diseasePCSK9 inhibitorsBempedoic acidLipoprotein(a)Angiopoietin-like protein3Apolipoprotein C-IIIApolipoprotein B-100DEENK Témalista::Orvostudomány::FarmakológiaHozzáférhető a 2022 decemberi felsőoktatási törvénymódosítás értelmében.